The evaluation of glioblastoma patients as a whole is increasingly using molecular profiling, which includes IDH status. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (2HG) rather than ketoglutarate, and this change alters cancer metabolism and causes oxidative stress [9]. Here, IDH2 is linked to glioblastoma.